Moderna announced chief commercial officer Arpay Garay is slated to leave the company in the coming months and will remain an advisor during the transition. Moderna CEO Stephane Bancel will take on responsibility for sales and marketing next year, the company said, working directly with the commercial team. (MarketWatch)
Pfizer announced that it plans to close its $43 billion acquisition of Seagen this week, in addition to building out a new oncology division next year. Chief commercial officer Angela Hwang would step down in tandem with the acquisition and Chris Boshoff would lead the new oncology business. (Reuters)
Walgreens Boots Alliance has entered into early talks over separating its U.K.-based Boots drugstore chain, including the possibility of an initial public offering in London. The drugstore chain could be valued at about $8.78 billion in any deal, citing people familiar with the matter. (Bloomberg)
The House passed a pharmacy benefit manager (PBM) reform package this week that would curtail certain practices by PBMs and bolster transparency. The Lower Costs, More Transparency Act would make PBMs and hospitals meet certain transparency rules, but getting it past the Senate is unlikely. (STAT News)
Johnson & Johnson and Genmab released data for the injectable version of their cancer drug Darzalex, hoping to move it into earlier lines of treatment. The Phase 3 results showed patients with multiple myeloma were 58% less likely to see their cancer progress when taking Darzalex Faspro, compared to patients on chemo alone. (Endpoints News)
To see yesterday’s Five things for pharma marketers to know, click here.
